TrimRX
US$ 21.44
novo nordisk glp-1 receptor agonist medications Wegovy for the Treatment of Chronic Weight Management, US Novo's Wegovy becomes first GLP-1
Description
In STEP-1 (semaglutide), lean mass decreased by ~9.7% while fat mass fell by ~19.3%, with the proportion of lean mass increasing by ~3 percentage points ( Limited preclinical and clinical data, particularly from MRI-based studies, suggest that skeletal muscle changes induced by GLP-1RAs may be adaptive
& McGuire, P
Am J Heal Pharm
Pederson RA, Brown JC
